NUVA - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the NuVasive Inc. Fourth Quarter and Full Year 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

to Vice conference External President like host, to Affairs. now Hatcher, Suzanne of would turn over the your I Internal and Thank you.

You begin. may

Suzanne Hatcher

and and call. Securities you, year this which with afternoon, thank Doug. the on to and filed earlier fourth Great, our on posted website X-K Welcome we issued Commission. XXXX been company's The quarter earnings is earnings has release, Exchange NuVasive's full Form

to posted also on financial accompany our supplemental website have We the discussion. information IR

like I'd call statements are and by from materially begin, NuVasive's Before if you today's or not based or assumptions remind such expressed expectations forward-looking those they statements. we discussions during uncertainties, materialize cause which results prove to will to the current other and include implied which factors to differ involve do could and be forward-looking risks on correct,

future no uncertainties news NuVasive Securities and assumes may respective releases that which or dates. update speak as periodic information risks and filings and NuVasive's of Additional are the their obligation forward-looking any with affect described statements in Commission. to Exchange results

the operating section be to the are development NuVasive's non-GAAP per cash also Investor from found to include financial These will earnings expenses, and Accounting news accordance sold, goods measures marketing and margin, directly financial administrative or today's financial our sales, Accepted of and of release generally the discussion information most supplementary not the non-GAAP calculated call This Reconciliations in expenses, measures that with We comparable GAAP. Relations which of cost Principles, these Generally several website. measures and as in research refer EBITDA. accessible are a include measures. gross margin, share, free financial GAAP flow may

Officer call Joining are Chief Financial Officer; on President. me the Matt Matt Link, Harbaugh, Chief Chris and Executive today Barry,

I'd to the Now call over Chris. with that, turn to like

Chris Barry

the level of preliminary good On turn I'll XXXX Suzanne. January on results results today key XXXX and with investments. XX. afternoon a year we results, year we planned full today's everyone. revenue overview fourth high in full quarter strategy you, then and XXXX line announced focuses Earlier And call, including Thank technology our reported to provide

Matt share X% well and full XXXX In X.X% details as XXXX, quarter financial and XXXX performance the on will fourth constant then additional Harbaugh, CFO, appointed reported our year $XXX came at full currency basis. revenue as growing billion, newly as on a guidance. in year

our and deliver comprehensive system specific operating Exela inclusive surgery. future while to of a and of expectation, these of approach driver enhancing workflow execution our room results lateral by best-in-class above continue result US continued business I a rates in backdrop of the driven the The adoption technology, market care, to advanced technologies as by system, by we spine against XXXX innovative XXXX single procedural the market. stable to system strength growth. our focused the techniques key view led spinal and hardware efficiency. training this encouraged a primarily These leverages be is position and patient growth of is and XXXX clinical were

on In focused with pleased as growth. the we on executed our saw out addition, we how across well that to the finished biologics XXXX. for and international to I'm line commercial on and this commentary side, growing selling teams additional business return how product entire of our will year each at trends range. sets financial fourth the share up quarter us top our relative guidance end Matt line portfolio,

growth, the we strategically a my while performed end that our at improving the margin areas lives. I well Overall, increased believe goal operating top as of results. we future of delivering point performance. investing on consistently to care revenue to serving For over consistently continuing year. was in balance full was business non-GAAP delivered key year of profitability XX.X%, surgery transforming a last improvement the advancing purpose reflection our basis profitability, XXXX. This same is Coming changing operational of XX achieved XXXX, and line at a with in time on into year, XXXX, this CEO role of growth our while the balance all

turn And I'd our like some and new you strategic to that to share XXXX updates plan. five-year supports with technology

outcomes to partners on to innovative technology new bringing and NuVasive portfolio with XXXX, an As across align spine key three we spine technology deliver company economic adoption XXXX. new surgery open than innovations the enabling products better spine to developing technologies our of to accelerate further that surgery, a increased reproducible are clinical and adoption predictable more support enable the XX invasive surgery. of dozen our industry, favorable anticipate disruptive surgeon goals. the once In again in spine Driving in on These investing this new focused and market. of segments needs more and focused less

and MIS lateral on our invasive and faster spine traditional open continue spine to benefits the comprehensive times segment the offers surgery, on system training we will to adoption surgeon the efforts market. and hospitals. segment than economic global both The MIS system. three support penetrate less patients growing most First, to The surgery enable the of and clinical further XXXX is

invasive deliver lateral from technology from XXXX. a an advanced is approach to and new increased a see half also surgery. and we The surgeons how clinical traditional good best-in-class this approach. for through spine less ability growth NuVasive new training year is adoption We're lateral the bending converting example surgeons to of of surgeons, for superior to tangible experienced lateral starting surgery curve Last back in saw demand the a momentum NuVasive XXXX

where name you're recently We adoption had the saw held and the about international practices. traction effect meeting it outside XXXX Germany XXXX has patients excited sales and we on our from of the Italy equally a US. there UK, discussed surgeons seeing few, And positive their in to

more cohere roughly in system. the XXXX, many Last categories. our performing and than XLIF data titanium support enable proliferating out focus spine powerful includes year, We approach and commercialization our to continue points under benefits outcomes, with In a procedures alpha we equating on enable less of comprehensive along to game using delivering Material surgery. more. PEEK surgery procedural several these implants Advanced cost XXXX save better are also to changing validates ALIF, launches interbodies for hours optimize to on savings including room, and the XD TLIF spinal and support differentiated estimate build patient the to generate full instrumentation outcomes, hospitals. associated to porous million value portfolio are Science key X,XXX we anesthesia related to operating data techniques. with of that This focused $XX are We'll that in developing These time lateral printed propositions we spine several of the the

currently studies spine for have better We and feedback on kick to positive several enable radiolucency to focus in to this clinical a planning to their and and off further growth. surface on implant outcomes continue patients. surgeons the and from the year novel bone more receive we of are implant porous as demonstrate To our structure importance for several underway, implants superiority efficacy spinal PEEK leader, the clinical validating position of the

portfolio, growth the headway We surgery an as treat trauma for development will is segments make market. market. rival solid to the dimension currently plan new which system This investing anterior of deformity, the penetrating of Another open targeted cervical on launching fixation and what and cervical a spine posterior as cervical plate to degeneration, to surgery. includes is well improve on a new

this the participate the as well to update who as commercial excited in our technology. new like very are an products currently strategy. prospects I'd and surgeons Our for to alpha on the are technology Pulse And enabling of these team, launches broader turn about

for last through several quarters. been Pulse beta we've previously, the discussed evaluations As working

platform's measuring system, verification to decision phase, deficiencies on different As surgeons insights the from the hospitals a during beta purpose lot to and feedback continue process, of is iterate the we of the important from development. platforms the validation operating of testing technical we've aspects room. performance in many the and to on made the Through learned gather gain use from the

will career. clinical work system it's that part and possible delivers the systems as the the expect a technology is the We been of release throughout I've of experience. development year. of And optimal on this foundational smooth many critical continue my in these types of a times

from to want it reiterate Pulse The strategy platform XXX% the I feedback customers' respond offering surgeons that our out exceeds of customers. the to of that a ensure continue modular, integrated excellent cases with to We expectations and platform and need receive capabilities nearly gate. hospital administrators. right resonates applicable is

same, remains continue the we the and Pulse and with development Pulse Our ahead further to forge will robotics in parallel. of strategy

in R&D XXXX. to turning Now

technology. core our spinal continue will We invest hardware enabling to products in

investments related key also In momentum. to operational these focused we'll further addition efforts, our fund sustain and several growth to globalization to improvements

to this specific One our key markets. fully again investment with regulation, this the packaging, participate undertaking enables us includes globalization, resources sterile to year. that an comply This which initiatives requires European global in area key attention is focused and to investment medical of device

grow way strategic investments company that XXXX, the like off growth. what in into and multiple to were long-term on phase ways we're disciplined you we the ahead goals. energized strong market. is impact efficiencies to the an addition, I'm of made have system with the making see by support a necessary drive In operational I'd foster to next to a What continue Coming in XXXX. leave These today we make and investments to planned

fully along the past improving over it excellence focus competitive allowing and a We're capabilities, drive true make year, increasing to us with leveraging and a on steady focused we've fulfillment to the front, advantage. On insource approach logistics our manufacturing our to operational improvement. global improvements made operational margin

Matt. I'd With over call to like turn that, the to now

Matt Harbaugh

everyone. Thank you, good And Chris. afternoon

Please with let call today's basis, many well on information financial started www.nuvasive.com further unless financial on covered as the get today's for as news are the of remind we to me noted Before financials, information refer non-GAAP reconciliations. in you otherwise. release supplemental measures a earnings regarding the that non-GAAP

NuVasive's a growth revenue on This X.X% and a grew strong portfolios. continues international. XXXX and Materials quarter Science fourth hardware to revenue hold million. reported adoption to was X.X% realization surgeon X.X% year-over-year, to we of was by market through driven procedure basis. $XXX.X performance implant product the across as on attributed continued spinal differentiated various constant around steady currency million, $XXX.X US take basis For is strategy up and hardware US system see This XXXX, implants. pull year-over-year above our Advanced

saw at growth growth outcome where targeted percent strategic Revenue single-digit of in low NuVasive from as our surgical prior year. historically revenue billing support An in $XX.X within increase cervical US million, under-penetrated. was a execution Service's segments We portfolio. resulting X.X% digit been open surgery have expected. Surgical spine support Clinical attributed in normalizing, to and came up over collections also mid-single we

to nearly the up return prior period. year in growth fourth over Biologics quarter, the X%

and to as synthetic We are as turn to portfolio see BBM include expand biologic headwinds. the corner we the well biologics annualizing offerings, price pleased mix to as have and worked competitive

Turning to We performance look This XX.X% was $XX.X this by for international, to forward revenue on fourth continue constant year-over-year in elevating a portfolios with than basis, NuVasive and XX.X% was XXXX, quarter year-over-year basis. growing pediatric more spine, a contributions orthopedic year-over-year as XX% currency region. growing on across reported, currency all and led regions. Europe specialized the constant million geographic

in performed the quarter in as digits the with high forward growing single made line XXXX. issue constraint set was in expectations, progress Asia-Pacific improve to internal

Mexico solid growth grew by currency the the primarily set in Latin availability of as constant in improved the half America basis, year. a mid On and throughout driven Brazil back double-digits,

pleased how at with business the year, our end ended the the range. guidance finishing international are of we Overall, upper

reserves new XX.X% point the margin or non-GAAP by Turning of as gross year as quarter product was driven manufacturing introductions. to operations, prior across a Gross well to basis of of improvement P&L, timing inventory was the XX.X%. for XXX expansion rest the efficiencies over fourth margin related

investments in based to SM&A XX% $XXX increased adjustments year, the in XX% medical quarter stock related to Pulse driven quarter primarily research revenue device X% over the expenses and year supply innovation investments by XX.X% The compared fourth increase XXXX. to fourth or in prior by development European The Non-GAAP totaled expenses million. increase costs, driven approximately revenue reflects in compensation increase primarily robotics. and from million, XXXX. price initiatives, R&D Non-GAAP mark-to-market $XX.X of or were stock of remaining or Pulse relates and of chain the by in expenses. our the Approximately revenue prior X.X% of X%

mentioned spending, in Fourth stock the XXXX based at was partially quarter insource came XX margin over prior by previously driven offset non-GAAP by and basis disciplined XX.X%, increase an operating manufacturing year. points compensation efficiencies of from primarily This headwind.

fourth $XX.X in million, XX.X%. Turning discreet non-GAAP effective diluted for adjustments our a rate in in lower for the non-GAAP the tax diluted $X.XX share Fourth quarter net one non-GAAP quarter compared non-GAAP non-GAAP last of expected tax reflects $X.X a income tax, the rate period. tax of net than per favorable million, earnings or time, non-GAAP This of million to the to EPS income expense of period year. was was resulting couple same of $X.XX $XX.X quarter or

net Turning our to quarter diluted earnings $X.XX same million period year. share million, of GAAP $XX.X were or of results, EPS GAAP diluted to last the of earnings the $XX.X or GAAP for GAAP XXXX fourth $X.XX compared per in

discuss a guidance. our Now quick of before I review XXXX year XXXX numbers full

Non-GAAP margin $XXX a in streamlining a offset efficiencies. prior year of basis gross previously Operating billion, by X% As expansion year to prior revenue XX.X%, full operating non-sales reported or was functions reinvestments constant and above on benefits margin margin business. in areas office of was and X.X% currency with primarily on growing XX.X% key as at back strategic for margin the driven basis, compared improvement, manufacturing Non-GAAP from the Chris the in a by stated, XX.X% was partially expansion gross by year. XXX basis. points driven and year came

in $XX.X compared prior EPS Full XX.X% diluted of our non-GAAP year full tax year, $XXX.X or $X.XX the diluted Non-GAAP and increase of per rate was million, net an year. was income other of was earnings and non-GAAP million, for non-GAAP XX.X%. $X.XX, expense share to income effective the

cash higher million, cash flow the to for was With million up million, XXXX over $XXX.X guidance for decrease and be and inventory growth cash free of $XXX.X regard to by in year for year. expenditures XXXX. driven year from Finally, The was our we equivalents prior X% estimate revenue instrument year to the by our was $XX.X million full range compared X%. for performance, XXXX, Year-end in to surgical prior operating $XXX sets. offset

immaterial expect currency an have to We impact.

these Let me within provide in provided expectations setting range. context some the

Our guidance reflects factors. a few internal macro and

expect remain XXXX. market experienced what rates to we to spine stable XXXX US to First, we at similar continue in in the

by implants. US for Materials XXXX spinal hardware driven trends Second, saw our the the of the line in we business system outlook remains with Science strong, XXXX, adoption similar Advanced and

low expect we international double sales the growth Third, digits. in

introductions X%, market to hardware driven the is adoption of grow XXXX on accelerated revenue training of spinal US and expected multiples by the at X% our product new to system.

for expand fully Coast We key training several capacity will the leverage East international. including and our best-in-class clinical by and locations, program surgeon development in expanding

to continue targeting market cervical TLIF, we where market open also an are we opportunity will traditional We and segments spine where deformity. surgery our focus gain like and have underrepresented, share, on

dozen We the respective products, continuing on the offering. new The and alpha year. to enabling look full first development a and will a implants the half competitive XXXX our of focus while about by these technology anticipated of in launches maintain products areas commercial in be commercialization launching half with instrumentation of back all

growing range positive decline at XXXX, US product realistic and historical This is also in don't and to continued IOM X% a to included tailwinds We believe pricing collections the continue. expect we range guidance comparisons lines based pressure is surgical on NCS that our this rate. biologics a X% which from of from growth. billing assumes tough support market

double strategy international international the continued digits. in of share XXXX, This to growth. product remains markets is going deeper business core For new is introductions driving for key grow taking on the delivering expected and our low predicated at

be line XXXX XXXX, plus what XX.X%. the with to of in and of This in expect last infrastructure, our Day packaging Moving at we operating XX.X% operating device range XX% European year's margin Investor the in we invest margin to by on is regulation for medical communicated XXXX. strategy our to driving to In must deliver sterile years. future we non-GAAP in growth and operating margin,

be achieve cadence heavily we the annualization and expect some our to year half contraction the to the second In XXXX. to year timing of we made stock clear, in terms expect fiscal first it investments half and of guidance. back margin and of of due in the throughout based the margin timing of of expansion XXXX, of growth, to half To year compensation, weighted be

year The to $X.XX range This repeat. company to a basis, one-time for from don't that diluted full several in we of diluted XXX. estimates expect of share share in non-GAAP headwinds the reflects to XXXX XXX GAAP range per a in XXXX earnings the per range we tax items estimate favorable $X.XX. On earnings

Relations press nuvasive.com on section on can today's or in Investor further expectations You find the GAAP details our release. in

One on capital than guidance, we capital by million, expenditures. driven which to free associated due increase to the increase an flow, expenditures This in education cash our cash disclosed headquarters improved Diego remains operating previous at is in flow, flow be investments expect free capital With final and by cash $XXX roadmap, be item San same. in the greater offset will instruments our allocation with manufacturing strong surgical new our primarily operations. facility packaging surgeon sterile strategy

will M&A, in potential balance we share We infrastructure program. continue repurchases well and to our also assets procedural under company will consider as and repurchase authorized our opportunistic as R&D, investments

in in to the make supply come. market, to to to in globalization performance positive NuVasive's patients' lives to XXXX, believe be and leading conclusion, we to thrive continue In in European and innovator improved foundational increase In that disruptive the remain investments chain and technology plan R&D ability to invest years initiatives operational We will spend predictable the outcomes. drive in on I drive enabling and spine. competitive enables technology changes efficiency

the growth you. these margin I and future. am through into expansion the returns Thank revenue investments significant confident will to company drive

Q&A I'd like to with And begin that, session. the

Operator

you. Thank

the first from a of comes with [Operator Instructions] conducting question. Josh session. Jennings Our be Company. & now will Please proceed question with Cowen line question-and-answer your We

Josh Jennings

thanks guess congratulations good on capabilities Matt in taking need expecting, just optimization. Chris, comments just you strong Hi, new and sounds incremental on a and color any maybe should piece in on of the or his position. a launch to features afternoon what of like share a to Congratulations navigation on it terms And Pulse maybe just I just can on XXXX was we your be and hoping, timing, follow-up XXXX. for questions. I follow-up is Pulse that the

in about Is parallel You couple incremental them answer there's Pulse timeline but robotics Thanks talked would development XXXX any robotics? in color So, a for of still be module. a for the that continued question on to questions question. great. taking the those there,

Chris Barry

really, Thanks, to kind previously be to beta this right we you're year Pulse and valuation And the do expecting our Josh. just communicated. commentary remainder extended been the Yes, I level in function minimal this the comments, Like be XXXX verification contribution the by timeframe. customers. throughout revenue really value think, We I of system market of well as the in efforts ensure on. very proposition, to is said previous validation my here a in the to has it received on of basically set, year, We're the expect just stable. our is

It's sure. that Our saying ability probably of system in in technologies that all I've a systems, the situation assertive different working let's absolutely that together. all more the the to make ensure bit been just little a are

way the the proposition market from let's testing need of really long to, in of That fulfilling pushes as strategy described. the the the the sense not and most value driving effective we we extend overwhelm urgency the Let's let us. technology as

Pulse and Pulse work still developing parallel. in extenuating that robotics beta does the with in actively technology To with we're parallel that testing end,

about It's development launch application. to of the move the through top a current But to robotic material we the the on final of launch Pulse, final insight with a have clearly, application of more market a on robotic application Pulse, plan as quickly that, thereafter. situation impact don't predicate XXXX the year, of robotic we Pulse, through. little Obviously and we has talk we with stages of robotics. bring early be this now then of to we'll move to the has but So the believe as with

Operator

the Stanley. Our Please David from next question. with with question comes Morgan of line Lewis your proceed

Unidentified Analyst

like questions. or as a 'XX. first for Mason Hi, for back David, a should this a half kind on the And here. thanks timeline make as is reinvestment? balance be Chris, going of follow-up system, for that, we this quick clarify more half you're the to going drop will have follow-up Thanks. question sounds year? It taking 'XX it This to to to base margin then increased full-scale and first the are a that iterate you on case as Or through expansion the this investments all appropriately at risk is to launch, to

Chris Barry

Thanks, This than we've we'll throughout is with -- any XXXX Mason. Basically we mid-XXXX. be launch already to in risk, desire what testing believe our what the we'll don't -- we'll fully puts doesn't other further do in extend beta described.

We investment are investing is the of year, organization robotics. Pulse strategy support heavily to continuing enabling and and inclusive this part that the in of technology overall

for we're stable, change any spend originally making ensuring most safe when we We're indicate the we year necessarily XXXX. could that the doesn't we and do market it confidence. so, the timeline sure profile. It we the just extends really in with product extending launch launched this on fully testing that throughout and effective just into our product had that the So, thought overall

Matt Harbaugh

from Yes. Mason, a this is contribution me, only Matt the nominal Harbaugh, thing year. I add -- Pulse excuse very this expect revenue do Matt, would And we is

guidance So, incorporates our Pulse. the today we that provided around thinking

Unidentified Analyst

from of US a is it. on factor some at? with then And most And opportunity could of is Pulse, this where market, we as contribution very trying the a you mainly support growing mean Thanks I to the Got kind have here much. year it call helpful. client declines so for get to in biologics potential we're surgical comps? see That's but flat. line it quick what follow-up

Matt Link

acquisitions benefit, normalization we of year had Matt were the some course in integrating updating as is the and benefits referenced earlier comments, billings. think, referenced one-time systems I it's last own this a and Link, -- across over Yes, our businesses. We the

And the side, we collection some to benefits so we that saw recur in on billing XXXX. expect and one-time don't

you normalize surgical the out, just pricing segment across driver see that's along as support. that with major there pressures the in So competitive we

Matt Harbaugh

Yes.

-- The is other this thing Harbaugh. Matt

and I'd that about a to like thing other was last that $XX full talked to incremental The year Matt is on basis collections billings this posted add one-time million that year. we in about revenue

Importantly million through quarter that it kind as in the last where of some year, consensus was though, of like $X of first projection. in at of on we considered we're gone doesn't was quarter, and the look for analyst that the first

So go back encourage we into consideration. and would just to you take that

Unidentified Analyst

Right.

Operator

Our of comes Suisse. your with proceed next Matt Please line question with question. Credit from Miksic the

Matt Miksic

taking for thanks guys, Hey the question.

up the you as that maybe in a mindful been or barriers? be plan bit it's past, what what it a TLIF, enter of you've timing to It's these was part efforts a keep it surgery talk of scale now? What I cervical, or the focus Why maybe, I described? of segments. we learned been opportunities business and appreciate of a talked have sort one. of with wondering spine you to the the couple some as color has about historical gear little bigger the do you company I'll So not and you deformity. from has Matt on But push challenges how open now times, about at the some a make if to Chris the of, are your just, should you could attack to its that. bigger to issue see

Matt Link

you've in blue I'll So to was unique Link, this seen bit is that. lateral. Matt Look, segment ocean MIS approach I or historically of novel think a take a specifically what and more

really portfolio focus we open the introduced that a and you the think two of that as full that and approach. driver offerings proceduralization compete course like decided described, of is market grown company, cervical line has the our around more internal to is particular, or Look, to to of the out last we've MIS and a opportunity the capabilities whether company other to new segment the spine areas conventional leverage us in number TLIF. solutions, component. an the major And comprehensive I complete to a regardless these a proceduralization develop for had seen we the As built product key which clinical TLIF we've it's in so years, over as in have

about lot to bridge spine talk Advanced Materials Materials material You really up we've the fixation at the hear instrumentation segments, product access Advanced applies us is us so there that bio as think out that looking as Science Science, the well. you the think fixation but well across in the taking, portfolio. enhance I with (technical entire posterior introductions that for a earlier, in just your I capabilities Chris a compatibility, advancing across huge PEEK novel interbody cervical adoption we a have round that opportunity as difficulty) in system to across And procedurally referenced innovation so towards the about, surgical platform. component just seen Modulus approach not answer interbody and porous we've proceduralization cervical our growth components, really and talked can cohere our as as plating cervical again Where all our

historical think the experience around proceduralization product again, key. So and leveraging I innovation really is

Matt Miksic

you. great. That's Thank

Operator

Our next with question comes question. from the your Please proceed Richard of Newitter SVB Leerink. line from

Richard Newitter

Hi, questions. thanks for the taking

think when remind then just the thing, what is Pulse components expect been, initiative, had now. both had benchmark just, the man, timelines in given robotics one, us approval for for Chris, remind just might the regular? commercialization? us timeframe both exactly you can for when And then us could the and first I Pulse or the for first then reasonable Paul's, robot. same be going your we prior And where it to it to and The you what and were milestone Thanks. the back

Chris Barry

have the Exactly. think I you numbers. think I Rich,

Matt Link

Yes.

that's Matt the the timeline So again, -- the more all really in provided and on robotics original commercialized, in Link, on really and beyond platform back Pulse this frame half detailed targeting was Pulse the the is platform robotics unveiling of focused first last provided a commercialization guidance we on never time XXXX, fall. We the full XXXX.

Richard Newitter

Okay.

back is now kind man holds? the off guess first that I So table the in XXXX of or in that part potentially of

Matt Link

Yes.

comments philosophy Pulse these it concepts an development reiterate of the applications earlier, processes we for of again is kind which Albeit, per Chris's robotics As reframe system of an ecosystem application. our behind a Pulse platform run is and major just one, in or parallel, an is application. everyone the to

efforts to So in concurrent evaluation as continued it's pathway parallel the current Pulse development to run well.

Richard Newitter

the momentum into to curious growth because over portion, also base to of training procedure other and and move of increased you what capture or of and of are to And users? front adopting of the And non-XLIF of then your pull fixation move starting see and in degree as Okay. the the respect past family, expect the to months. contribution or have to the maybe XX people overall momentum coming think Thanks. kind you through of outside well from on similar you, what the lateral the kind start that I'd to users, you XXXX, about XXXX an Are XLIF and question friends installed should with a parts posterior XXXX? next type into as opportunity be we you drives moving of your more Are you you aspect XXXX.

Matt Link

Yes.

try that two tackle to I'll waves. in So

in of and run it Again to broken those the customer of a of from hasn't users. lateral users XXXX out So current new XXXX process concurrently. been sort like segmentation that lateral on training perspective characterization the

proceduralization opportunity to the surgery So we of of and have the clinical expand application lateral tools with seen the and utility both XXXX.

utilization existing the within we've expanded an lateral customer base. So,

lateral inability the from lower the also users approach, and we've as the an think seen this adoption the perhaps specifically with strong segments the challenges the looked limitations a them of spine new standard to lateral who created lateral of direct access important access of pretty LXSX at into repositioning has for I point patient, portfolio. and the very some

to in here brand Coast in training of heavily and across San well also as to we think competitive Diego. well and the We're users. going as going adoption comments, new see segments surgeon center back so training lateral to And training with as expanding we're continue invest our continue surgeons as Again, I internationally. East Chris's experience on earlier capabilities to two those

focused efforts opportunity equity. clinical program development to to the very CPD through or our our So for professional optimize on continue

is many a procedural we provided. expand as we to meaningful portfolio. rest for oftentimes procedure that our XLIF pull-through goal in fact accessible based a a flagship market From create of our making draft on the to way, And more to the overall think really as a on the by the occasions, I lateral referred to solutions surgeon perspective, customers said strong more tends we've it

question. think you I your in referenced

One of our with of see strongest of do within the areas pull customers, portfolio fixation. our across other segments clearly we encouraging. XXXX posterior continued uptake which through But is

Operator

with Zimmerman of BTIG. from Our comes with line the question your Ryan Please next proceed question.

Ryan Zimmerman

Thank you.

we your monitoring how, what do kind a Thank are support surgical biologics want But, XXXX. and could kind So, follow-up it's steady surgical US support or some in if components that biologics it in in the when is growth part guidance early you And what on clouded market? of I look the of your I just you. there to to one-time underlying like? does of the on get expand for assumptions steady-state it that guidance. And state whether view? call say appreciate

Matt Harbaugh

Yes.

this So is Matt Harbaugh.

kind the color. more it Matt the little and as XXXX of Link start of with that a guidance of for kind we just what drivers then I'll see to to today, me provided turn over we Let provide

said earlier billings of As through year. $XX growth last had first is billings was and quarter on the incremental as the NCS we to I in X in which I collections, and mentioned that going million million of And revenue earlier, normalize. collections

see And from a so will that. decline we definitely

year. So the last enjoyed we benefit

are also businesses. pricing continue to competitive the We going IOM to some see product service the line in within pressures

also that's factored so there. And in

more then likely come today. guidance happy forecast while the earlier, in to As the sales minimal in in with XXXX. It's that's Biologics, we were the provided I or in saw low we fourth the growth, in the contribution regard mentioned also that capital from to very single-digit quarter. with and And we results

Matt Link

Yes, I'll biologics. respect just comment, with the to

requirements market to the we very portfolio stem that in biologics. building like expect are, to an we lower-priced our as We be in some options, in alternative with and particular growth. premium been options judicious it We range of as market can to pricing out the ensure with have sort to what address think of that cell sort relates biologics

the expect we remain so to other in that And procedural growth to measures. continue and manage range of and market that attachment through

Ryan Zimmerman

Thank you.

Operator

proceed your Our from question. with with line Matt Sandler. O'Brien next of the comes question Please Piper

Matt O'Brien

continue for that of to a surgical And months likely And fair next And man fair I there maybe but may say the very is that taking delayed the lot launch, few versus actual questions. months is XXXX components first is compelling, was be understand what however three a that it for thinking the sorry this on sometime for year, Thanks is say I'm it limited arm the the system. to the to components? but you in will down be a robot, it to path today Pulse to characterization characterization arm anticipation Afternoon. in of early is have six been going ago. a

Chris Barry

we we as development realm ballpark in keep consideration. the some go is again opportunity. to potentially in and still through that first I man still think within and that saying where then the of of accurate, the have year system, of testing you're application as the this do We ultimately is I in robotics. the But of of also final to of desire our It's Pulse although house out have what believe

forging application I the ahead entrants robotic a our that wouldn't material I with Pulse have say with arm. -- would doesn't and don't, on our what with feel you're the is steam current necessarily ahead situation full But the in ballpark. the like I So impact that market we're saying in

Matt O'Brien

Okay.

and the major No changes at on So design delay modest still technology. a very needed? bullish end world the of the is

Chris Barry

Absolutely.

Matt O'Brien

to and would see XX% bigger I of projection know this about you CAGAR through to little point But year. that what it weren't specific XX% as bit far And side or that levels then Chris international grow growth a you've period. that the you as things, per talked on we outlook XX% XX% they year below gets Matt, of the over get Okay. XXXX, as harder when

And of that committed year? bigger do are to up that XX% start we how in CAGAR? Should to a and then international we still business ramp Or we next 'XX? So, think 'XX, the performance see about that?

Chris Barry

a the of It's any could swing double different of if very national market. work about digits. the capability it talk about about A the I'm about supports growth. operational period still to XX%, CAGAR more the in based obviously again bullish time. upon over myriad think year longer It think building low you given it's our And probably a things. the we that of lot in was international

to get robust, operationally our in supply a very we've scenario. a got in So efficient chain

that we right internationally. And growth gated can I somewhat support at So times. we're think widespread now still

us about heard availability. talk You've set

Some full-scale to of predicates efforts. these items unlock are globalization

gating the So that that of logistics fully global to to out our advantage driving world-class operational a of end, opportunity. our supply and robust really to scale a to full ability generate really to and us excellence take item global thermal chain, to is operational focus on -- continuing extent, efficiency to or on build for a and

consistent. very about the think Day. I at Investor story So, What we talked is

number. and will said, more operational year I enabling key robust resonate think elsewhere. growth of as some I is technologies, markets these And and capability in we we growth a also a solid launched Europe the as build next as which

that strat that story back tailwind half in [ph] I the think that's the what to plan. growth gives of us

Matt O'Brien

Thank you. Got it.

Chris Barry

Yes. Thank you.

Operator

next with Please with line your Marcus of comes the question JPMorgan. proceed question. Our Robert from

Robert Marcus

to Great, I and thanks where margin And and than greater extra ask spend from minute you color doing for million think is, not, up where about give I looks interest more then just like you heard $XXX talk thanks. on taking we the one. XXXX? just I'll flow, could guidance see coming about financial north $XXX tax was year. Two for little spending XXX. in ones, expect hoping operating maybe cash million if us a Should is ended We something in the free the you just XXXX's it shares question. and a on how the of And

Matt Harbaugh

you Yes, bet.

took XX% did the shares one-time excellent in saw $XX historically. line to will of tax generally But thinking about and going a job favorability structure. And million, $XX be in we've make kind see rate XX%, outstanding. to share, say more rate rate interest earnings perspective, what a aided rate. an converts $XX From the that we are we did of fourth So, in expect on guidance line that million a with with our XXXX. team we there it rate of historical have if be I'd what around in million, The we've basis. kind per we that XXXX. some full some around was kind think an cap consideration decisions tax our and from posted in you $XX million, we the Obviously, I in do that given tax akin perspective, we tax year on But into tax were we more range guidance predicted to to be similarly shares took in as quarter the earnings particularly down. get the tax our

see So significantly don't that. I anything moving

say investments we're you to in the $XXX would around number to flow, million here just range right making that regard in I do the some significant that's your about now. of use question of the work am prepared that we're free foresee With of the I We headquarters. kind a sure the capital heard process cash in remarks. doing some at

being medical regulations. investments sterile European We some into supply device also the pack, chain, that going the and then have significant our

able sets some putting rolled to long-term at pressure Day. capital strategic to but that's really the up we deliver be Investor spend, plan that on So out us on that our

making of to of shares the off the way some $XX characterizing me, is going Excuse where definitely $XX long-term we've we're investments a outstanding. is I investment, say year definitely to future. So million to the been and XXXX meant is that internally that pay infrastructure million in

Operator

of line the with your from Raj comes with question Denhoy Please next Our question. Jefferies. proceed

Unidentified Analyst

This [ph] Chris on Raj. have for one I Thank is one you. and Anthony and for Matt. XXXX, strategy then

question actually penetration is what where Rich's the it's into existing couple I'm this to go wondering and question, NuVasive that your Just the just point, at a next follow-up can on over accounts on XXX, that And would be accounts? those through seeing of Matt. be, price years? And would for strategy volume and is follow-up Chris pull the a the quick what and you're then, on

You're M&A. there restructuring cavity alums, both long-term had and the DNA

there, next looking the to few where out see the you temperature and just take playing restructuring Thanks. I'm over M&A So years.

Matt Link

Yes.

existing to base. So XXXX is of, customer XX% to spoken have sort generally with XX% Link training on Matt of in penetration, penetration our we respect the of range around the say

so And continue we so to mentioned the previously. investments on build expect through do that, to we'll and

on also our talked pull tend we we with reflected values case based associated see capture per through, per sort more is of higher levels procedural that's case. through As XLIF about larger attachment to opportunity the oftentimes

And so extra those overall respect are, with XXXX continued the to to tailwinds portfolio performance. be strong

Chris Barry

And Yes. this Chris. is

then were company. going I On question, those the to become sets and active M&A. of grow came as point strategic us for you much we months so runway the sort the roughly in wanted that over really the or as me strategy put pull to understanding year about we past it, finer ago, Day, think more an a in XX Investor to of, we the up articulated of levers our really and get And to to

portfolio potentially ahead broadly then out deliver with robotics efforts through further our looking the in in we're that about do of the commitments we around could to accelerate technologies, really get of key front made And equipping lateral, of looking how our at we've clearly other that August. to business globalization we we -- So deformity. got Pulse, a we our back globalization we've the at opportunities our furthering MIS And in cervical of we've development area. amount Pulse XXXX that about we do how and feel segments our and or surgery deliver equipping through actively open accelerate and M&A, like portfolio some the focus talked growth with runway on significant that our talked system

I of we've bullish. bit to that I'm continue. last a year. taken the breath sort of like a got, over of But a feel bit don't we So I expect

is consider really to primary a anxious grow I'm to business. really M&A the pull we So lever that

As far as it I'll to restructuring, over Matt. turn

Matt Harbaugh

and definitely look we're say goes the of States We've look out. take to results particularly to both we returns look couple for the efforts I'd much in to invest very at and XXXX, also long-term I'd strategic businesses, our Make to order through things at at costs, going Sure. be want out you all we areas, other actually capital IT And deliver I, question. in investment a to delivering require the to is optimization long-term. and the OpEx the Matt and Ohio, countries, we between the will the we are there all the very DNA, to you be but in on focused plan returns, to world. that going in definitely mentioned we're very sometimes Chris take more to underlying going may back which OpEx. done focus but get have work there the say seen on thinking Harbaugh. profitability more manufacturing. good order out United that to put efficiency for that are Thank you on focused of on We sure are some in year. but around and mine we that those in we're we that laid some of of last a

progress, good really is coming but to come made in there we've the years. think I more

your on to we focused optimization. going to yes, question be really answer the are So is

Unidentified Analyst

Thank you.

Operator

question. Our line comes of from Fargo. Please your question with with Wells proceed Shagun next the Singh

Shagun Singh

which the guys expansion drive you so half, for back in you in goals thinking the about us expectation LRP, you there magnitude operating in understand have I the on one help will the question. I cadence you of the first contraction investments or relative taking the And the your us guess would be the Thank give Can or the the in half. margins. back how the in half to half? towards had you're much that stated was front

hundred margins XX ballpark? XXXX? points right we still should you. in plus thereafter? up how the in basis step think And the basis about Thank XXX So then, Is XX to points

Matt Harbaugh

Yes.

that a see We going we'll year on the is second. perspective, and to first you basis of lot floor bit significant two on expenses data first the of non-GAAP that a guidance the our XX.X. I That's the way a compensation being work would point share there We're highlight in our have So that We've a to medical an to margin in half but we're that infrastructure and the stock to is operating that a have going particular, as definitely so XX.X continue first that the we occur in and we're quarter We've device got would there. invest to quarters, the to going got sterile pack. work that from we EU in Particularly, of basis, today. way full believe that I speak. second pressure need through. that make to correlates Pulse we'll through. making price, with realize to to opportunity our investments will In

as on we year pressure out lift work operating as and so, year in first should issues. putting half these that you're a income the of way of kind then our second and you the modeling And the some seeing back be through of the in quarter,

margin going helping also more top also that's of in add, would back introductions, which some half the but I which us also offset of us us help will thing other in bring The on help expenses. as year is the the to product it line, these will new

is So plan. back loaded a end it definitely

Chris Barry

committed we're guidance driving gave that Investor by plan, number the XX% As the XXXX. really far as Day, we at a still to the

what exact over course set we give move of investments as make we into we in forward. hesitant we an I'm made margin to for XXXX believe up -- of the So XXXX the really outer number expansion always over us years, course but the

Shagun Singh

up then, it the the if it. gets here. in could EUMDR, follow I future got on implemented I just And near

question. does are Just for Thank you thoughts strategy? how likely how your also as product does what some Especially latest it and you impact it and international your-- SKUs you wondering exit impact reduce your taking the lines. your

Chris Barry

us our seeing the around the this that's the and we just think, in our in incur time, an based a having numbers a good to short-term, comply the allows to a Over scenario that all sterile a the reflected Yes, regulation we're streamlined that insure it Europe. It build obviously in impact resourcing documents you're a having exactly that area thing. all burden and packaging CASM I that order. chance does MBR associated upon having forces expense don't year, have that portfolio right. put in you to us expense where create broader streamline of think to It to all are portfolio. does you're think with, into I strategy. capability the point, forth portfolio that in the having more you've bad will We're

of adhere source five-year obviously globalization period, biggest it's a the and for, we've CMR in as countries the existential over scenario, engine a growth our but to I revenue actually in I but the European in think our good contributing us regulations. that to, for we've you single to the is we think about it's got in that short-term, challenging about back that definitely, participate markets that's participate what going are thing, markets in focus CMR a it's talked opinion, by primary all being the to got European fully participate with

does forward. It definitely of the short-term you're to expense overcome. You're a bolus create a create right. it going that we're in having does streamlined But definitely portfolio

Shagun Singh

Thank you so much.

Chris Barry

Thank you.

Operator

of proceed question. your Please Our the SunTrust. Kalia next Krum with comes question from with line

Kalia Krum

taking Hi question. guys, much so thanks our for

one So, the implant market. one on the then robot spinal on and

about So really first about are system, and excited on excited the robot, I are robotic reps mean I know robotics. your the customers your

ahead guys for are timelines you you giving do how And that customers willing of of right expectations are wait you to launch? What application? sort warming up your now? you So current your them? excitement the robotic and manage surgeon they're you are Are finding

Matt Link

so acknowledge the enthusiasm Yes, for this is that we Look market robotics. in Matt Link. the

we've the think what really said Pulse, also and is all that's current what step and a is to clinical with broad desired and as platform applications be you road measured along utility. building the is take back map And the assess, a have future I state. capability been have that and

becomes provide clinical spine to robotics cases refer capability of we the clinical of As foundation for integration support application. applications incremental, those the that decision-making and that then and XXX% through future

a in, clinical number to from respect of If seeking. where with hear application the or relatively platform of percent at broader our I that's the the today have can you there's look market participate to a that still desire we're with think customers, case and an what a utility. robot we cases lightly And utilized consistently

that. as referenced towards we're continue earlier, So, going we to to build

Chris Barry

on way with warming our customers that, we're add up of done. the just I'll is line that in very kind always what much we've

You And really increase work specifically our out that technology, portfolio the we've of We robotics, strategy to portfolio think and and some that got enabling provide an portfolio world-class is world-class the we the in done instrumentation Advanced hone on our to to where biologics utilization got fixation. we that fully And Science like of to technologies make access. about surround around extension we sure we Material round with of there. we've current robust effectiveness a focus that provide we and ensure continued interbodies. have

a that solution, story robotics of is an not a strategy. our says is our that tell to a part it continue part strategy, of independent we So is proceduralization and

with I think it customers. resonates our

the anxious many by robotics, in of think Pulse far. we ahead but put strategies -- to markets the and Clearly, thus we're strategy resonates I think proceduralization ways we're I we're in having solidify with come think really the I of I it with pack that the to ahead proceduralization think that market. the

Kalia Krum

makes level curious of for high understood a that No, you're or kind okay. on ton puts it, out ordinary market, takes sense. any implant spinal seeing just of of or Got then hearing. I'm And

seems is like both there were out about then than ago a And have read mix less yes, month the physician acting out spines. stimulation a spinal paradigm. more those little now your unique of and it given on treatment guidelines put on neuromonitoring Just and moving conversation specifically, in sort cord

you what be or hearing of kind guys generally there? So are just different might speaking, seeing that

Matt Link

Yes.

as the prior point, nothing calls conversations. So material shift we we at we've change. is our disruption haven't seen We market market materially and that this in see the seen any have commented stable, to in

enabling other still, And I recognize segment conservative back on ultimately the when we measures pain in the that you appropriately platforms, opportunity facilitate intervention, certainly and to technologies advancement in particular a a and population appropriate, and low indicated in think, respect indicated believe our appropriately with to side, of are we more MIS reproducible particular. of to can and is continue spinal surgery. managing with address surgery. While alternative interventions particular a therapies, for the technology predictable wider There's that well-established there's that for treatment patient is

see conditions. market as at we this So point stable, monitor continue to we'll it but the

Kalia Krum

much. you thank so guys right, All

Chris Barry

Thank you.

Operator

closing further remarks. I'd no questions. call back to to hand are the Barry like There Mr. for

Chris Barry

to We the place, Doug. forward you, And to participating our in look our can With and you thank you along all with earnings guidance Thank set, value speaking quarter. in NuVasive we optimistic you. next future today. Thank call expectations shareholders. about I'm of the deliver strategy five-year the strong business with

Operator

and your today's participation. Ladies you does for conclude gentlemen, Thank teleconference. this

You time this have a may at day. and wonderful disconnect your lines

Nuvasive (NUVA) 20 Feb 202019 Q4 Earnings call transcript